UMass, partner land Navy antimicrobial research grant

By Mass High Tech Staff

Video Gallery

MHT's Marc Songini: RI plans launch of cord blood center

MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban

Gen9 receives $395K in debt financing [May 22, 2012]

Report: Foreign countries want to lure US biotechs [May 21, 2012]

Former Secretaries Rubin, Paulson to speak at BIO [May 21, 2012]

XenneX completes merger with LifeMap Sciences [May 21, 2012]

The University of Massachusetts and its research partner PolyMedix Inc. have won a Navy grant to study the best antimicrobial compounds for military uses.

The Office of Naval Research awarded UMass and Pennsylvania-based PolyMedix (OTC BB: PYMX) the $99,000 Phase 1 Small Business Technology Transfer (STTR) contract to discover lead antimicrobial compounds based on PolyMedix’s novel small molecule defensin-mimetics for activity against bacterial pathogens, with a particular focus on Acinetobacter. Acinetobacter is a Gram-negative bacteria which can cause pneumonia, and is highly resistant to currently available antibiotic drugs.

PolyMedix will get $69,890 in the first phase of the contract, to be paid out over six months, with an optional extension which may provide an additional $29,948 of funding for continued work which would be done together with Gregory Tew of the University of Massachusetts Amherst.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.